PMID- 15074465
OWN - NLM
STAT- MEDLINE
DCOM- 20041005
LR  - 20071114
IS  - 1433-6510 (Print)
IS  - 1433-6510 (Linking)
VI  - 50
IP  - 3-4
DP  - 2004
TI  - Mechanisms of IVIG action in immune thrombocytopenic purpura.
PG  - 133-40
AB  - Intravenous immunoglobulin (IVIG) has been an important therapy of immune 
      thrombocytopenic purpura (ITP) for more than 20 years; however, questions still 
      remain regarding the mechanisms of IVIG action in ITP. Recent reviews have 
      focused on the hypotheses that IVIG effects are mediated via inhibition of 
      Fc-receptor mediated platelet phagocytosis, suppression of anti-platelet antibody 
      production, and anti-idiotypic inhibition of anti-platelet antibodies; however, 
      new research suggests that a significant portion of IVIG benefit may be due to 
      IVIG-mediated acceleration of the elimination of anti-platelet antibodies. It is 
      anticipated that promising new therapies of ITP, and other autoimmune conditions, 
      will be developed based on a better understanding of IVIG mechanism of action.
FAU - Hansen, Ryan J
AU  - Hansen RJ
AD  - Department of Pharmaceutical Sciences, University at Buffalo, The State 
      University of New York, Buffalo, New York 14260, USA.
FAU - Balthasar, Joseph P
AU  - Balthasar JP
LA  - eng
GR  - HL67347/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PT  - Review
PL  - Germany
TA  - Clin Lab
JT  - Clinical laboratory
JID - 9705611
RN  - 0 (Autoantibodies)
RN  - 0 (Immunoglobulins, Intravenous)
SB  - IM
MH  - Animals
MH  - Autoantibodies/immunology
MH  - Blood Platelets/immunology
MH  - Humans
MH  - *Immunization, Passive
MH  - Immunoglobulins, Intravenous/*administration & dosage
MH  - Purpura, Thrombocytopenic, Idiopathic/*immunology/*therapy
RF  - 70
EDAT- 2004/04/13 05:00
MHDA- 2004/10/06 09:00
CRDT- 2004/04/13 05:00
PHST- 2004/04/13 05:00 [pubmed]
PHST- 2004/10/06 09:00 [medline]
PHST- 2004/04/13 05:00 [entrez]
PST - ppublish
SO  - Clin Lab. 2004;50(3-4):133-40.